PNC Financial Services Group, Inc. has disclosed an increase in its ownership stake in the Invesco China Technology ETF, now holding 4.89% of the fund. This update comes from a recent SEC filing, which highlights PNC's strategic investment in the technology sector through the Invesco Exchange-Traded Fund Trust II.
The filing, dated November 5, 2026, indicates that PNC beneficially owns 2,255,689 shares of the ETF. Of these, 2,249,181 shares have sole voting power, while 1,125 shares are shared. Additionally, PNC has sole dispositive power over 1,828,553 shares and shared dispositive power over 426,835 shares.
Background
Invesco Exchange-Traded Fund Trust II is an investment entity that manages various exchange-traded funds (ETFs). The recent filing is part of a series of disclosures, with the last notable one being an NPORT-P filing on October 30, 2026. The trust is known for its focus on providing investors with access to various market sectors, including technology.
What the Filing Says
The SEC filing reveals that PNC Financial Services Group has acquired its stake in the Invesco China Technology ETF as part of its broader investment strategy. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business." This indicates that the shares were not purchased with the intent to influence control over the ETF.
Impact
This development may impact various stakeholders, including investors in the Invesco China Technology ETF and competitors within the investment management industry. PNC's significant stake could influence the ETF's market positioning and attract further interest from other institutional investors.
What's Next
The filing does not specify any immediate next steps regarding PNC's investment or the Invesco China Technology ETF.
Read Next
VIVMARK RESIDENTIAL Completes Major Acquisition
Processa Pharmaceuticals Updates Stockholders on Strategy
Processa Pharmaceuticals Announces Special Meeting for Stockholders
Processa Pharmaceuticals Shares Strategic Update in SEC Filing
Lifecore Biomedical receives HSR approval for merger
Avalo Therapeutics Enters $200M Sales Agreement with Jefferies









